Mobocertinib added in NICE guidelines
NICE guidelines have added the guidance on mobocertinib to the systemic anti-cancer therapy treatment pathways for advanced non-small-cell lung cancer.
They would like your feedback on how the treatment pathways present content from different sources (NICE technology appraisal guidance, guideline recommendations, and expert input). To comment, go to the link below on systemic anti-cancer therapy for advanced non-small-cell lung cancer and fill in the pop-up survey.
Recent Posts
Biotechnology Act Europe Driving Innovation and Investment in Life Sciences
The Biotechnology Act Europe offers a once-in-a-generation chance to turn the continent’s world-class life sciences research into scalable commercial successes that remain in Europe rather than migrating elsewhere. By tackling regulatory fragmentation and sharpening investment signals, the legisl...
Rising Trends in Early-Onset Colorectal Cancer Burden
Early-onset colorectal cancer is rising sharply among adults under 50, even as overall colorectal cancer incidence and mortality have declined through improved prevention and treatment. Contemporary adults aged 30 to 40 now face higher risks at younger ages than their grandparents did, with the d...
Enhancing Health Technology Assessment Through Real-World Evidence in Portugal
Real-world evidence Portugal has moved from supplementary tool to statutory requirement under Decree-Law 118/2026, which compels national health systems to share interoperable data so that promised outcomes can be verified after medicines and devices reach patients. The legislation converts one-t...